Safety and Performance Assessment of the Decongestant Seawater Spray Pocket Valve Enriched With Essential Oils in Patients With Acute Rhinitis Associated With Nasal Obstruction: "DEVALPO"

Inclusion Criteria:

• 1. Patient ≥ 12 years.
• 2. Patient with acute rhinitis associated with nasal obstruction during infectiousepisodes such as rhinopharyngitis (cold), rhinosinusitis, or during non-infectiousepisodes such as allergic rhinitis.
• 3. a. Informed adult patient who has given written consent prior to any studyspecific procedure. b. Informed minor patient who has given assent and whose legalguardians have given written consent prior to any study-specific procedure.
• 4. Patient able to meet the study requirements for monitoring, spray use, andquestionnaire completion.
• 5. Patient affiliated to a social security scheme.

Exclusion Criteria:

• 1. Pregnant and/or breastfeeding woman
• 2. Hypersensitivity to seawater and/or known allergies to any of the ingredients ofthe spray.
• 3. Diseases causing narrowing of the airways (e.g. asthma, chronic obstructivepulmonary disease (COPD)) and/or respiratory insufficiency.
• 4. Patients with uncontrolled asthma (GINA score greater than or equal to 4)
• 5. Patients undergoing allergy desensitization
• 6. Patients suffering from chronic nasal obstruction due to a deformation of thenasal wall or nasal polyps. creams or gels.
• 7. Patients taking local and systemic vasoconstrictors, corticosteroids,nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and local antiseptics.
• 8. Concomitant use of other nasal sprays, essential oils for local nasal use,creams, or gels for the nose.
• 9. Patients under guardianship, conservatorship, or legal protection.